{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:24:35Z","timestamp":1793413475738,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012685","name":"Latvijas Universit\u0101tes Fonds","doi-asserted-by":"publisher","award":["Project number 2261"],"award-info":[{"award-number":["Project number 2261"]}],"id":[{"id":"10.13039\/501100012685","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012685","name":"Latvijas Universit\u0101tes Fonds","doi-asserted-by":"publisher","award":["Project number 2261"],"award-info":[{"award-number":["Project number 2261"]}],"id":[{"id":"10.13039\/501100012685","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12035-025-05079-x","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T02:38:54Z","timestamp":1749177534000},"page":"13029-13043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low-Dose Intranasal Metformin Exerts Neuroprotective Effects in a Rat Model of Sporadic Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"62","author":[{"given":"Vladislava","family":"Kurtukova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selen","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Pupure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar\u012bna","family":"Narbute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Muceniece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimirs","family":"Pilipenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"5079_CR1","doi-asserted-by":"publisher","unstructured":"Vignon A, Salvador-Prince L, Lehmann S et al (2021) Deconstructing Alzheimer\u2019s disease: how to bridge the gap between experimental models and the human pathology? Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22168769","DOI":"10.3390\/ijms22168769"},{"key":"5079_CR2","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols E, Steinmetz JD, Vollset SE et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7:e105\u2013e125. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8","journal-title":"Lancet Public Health"},{"key":"5079_CR3","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/ALZ.13809","volume":"20","author":"Alzheimer\u2019s Association","year":"2024","unstructured":"Alzheimer\u2019s Association (2024) 2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 20:3708\u20133821. https:\/\/doi.org\/10.1002\/ALZ.13809","journal-title":"Alzheimers Dement"},{"key":"5079_CR4","doi-asserted-by":"publisher","unstructured":"Weintraub S, Wicklund AH, Salmon DP (2012) The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med 2. https:\/\/doi.org\/10.1101\/CSHPERSPECT.A006171","DOI":"10.1101\/CSHPERSPECT.A006171"},{"key":"5079_CR5","doi-asserted-by":"publisher","unstructured":"Sheppard O, Coleman M (2020) Alzheimer\u2019s disease: etiology, neuropathology and pathogenesis. Alzheimer\u2019s Dis: Drug Discov 1\u201322. https:\/\/doi.org\/10.36255\/EXONPUBLICATIONS.ALZHEIMERSDISEASE.2020.CH1","DOI":"10.36255\/EXONPUBLICATIONS.ALZHEIMERSDISEASE.2020.CH1"},{"key":"5079_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41392-019-0071-8","volume":"4","author":"PP Liu","year":"2019","unstructured":"Liu PP, Xie Y, Meng XY, Kang JS (2019) History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease. Signal Transduct Target Ther 4:1\u201322. https:\/\/doi.org\/10.1038\/S41392-019-0071-8","journal-title":"Signal Transduct Target Ther"},{"key":"5079_CR7","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/J.CELL.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker M, Walker LC (2023) Alzheimer\u2019s disease: from immunotherapy to immunoprevention. Cell 186:4260. https:\/\/doi.org\/10.1016\/J.CELL.2023.08.021","journal-title":"Cell"},{"key":"5079_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/S12967-024-05248-X","volume":"22","author":"LX Yi","year":"2024","unstructured":"Yi LX, Tan EK, Zhou ZD (2024) Passive immunotherapy for Alzheimer\u2019s disease: challenges & future directions. J Transl Med 22:430. https:\/\/doi.org\/10.1186\/S12967-024-05248-X","journal-title":"J Transl Med"},{"key":"5079_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/J.PNEUROBIO.2013.06.004","volume":"108","author":"Z Chen","year":"2013","unstructured":"Chen Z, Zhong C (2013) Decoding Alzheimer\u2019s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog Neurobiol 108:21\u201343. https:\/\/doi.org\/10.1016\/J.PNEUROBIO.2013.06.004","journal-title":"Prog Neurobiol"},{"key":"5079_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JAD-121867","volume":"35","author":"L Mosconi","year":"2013","unstructured":"Mosconi L, Andrews RD, Matthewsa DC (2013) Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia. J Alzheimers Dis 35:509\u2013524. https:\/\/doi.org\/10.3233\/JAD-121867","journal-title":"J Alzheimers Dis"},{"key":"5079_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/J.JALZ.2017.09.011","volume":"14","author":"Y An","year":"2017","unstructured":"An Y, Varma VR, Varma S et al (2017) Evidence for brain glucose dysregulation in Alzheimer\u2019s disease. Alzheimers Dement 14:318. https:\/\/doi.org\/10.1016\/J.JALZ.2017.09.011","journal-title":"Alzheimers Dement"},{"key":"5079_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/S13195-019-0512-1","volume":"11","author":"YN Ou","year":"2019","unstructured":"Ou YN, Xu W, Li JQ et al (2019) FDG-PET as an independent biomarker for Alzheimer\u2019s biological diagnosis: a longitudinal study. Alzheimers Res Ther 11:57. https:\/\/doi.org\/10.1186\/S13195-019-0512-1","journal-title":"Alzheimers Res Ther"},{"key":"5079_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/193229680800200619","volume":"2","author":"SM De la Monte","year":"2008","unstructured":"De la Monte SM, JackR W (2008) Alzheimer\u2019s disease is type 3 diabetes\u2014evidence reviewed. J Diabetes Sci Technol 2:1101\u20131113. https:\/\/doi.org\/10.1177\/193229680800200619","journal-title":"J Diabetes Sci Technol"},{"key":"5079_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13195-022-00996-8","volume":"14","author":"A Gonz\u00e1lez","year":"2022","unstructured":"Gonz\u00e1lez A, Calf\u00edo C, Churruca M, Maccioni RB (2022) Glucose metabolism and AD: evidence for a potential diabetes type 3. Alzheimer\u2019s Res Ther 14:1\u201311. https:\/\/doi.org\/10.1186\/S13195-022-00996-8","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"5079_CR15","doi-asserted-by":"publisher","unstructured":"Michailidis M, Moraitou D, Tata DA et al (2022) Alzheimer\u2019s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer\u2019s disease and type 2 diabetes. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/IJMS23052687","DOI":"10.3390\/IJMS23052687"},{"key":"5079_CR16","doi-asserted-by":"publisher","first-page":"18227","DOI":"10.1523\/JNEUROSCI.3266-12.2012","volume":"32","author":"WJ Jagust","year":"2012","unstructured":"Jagust WJ, Landau SM (2012) Apolipoprotein E, not fibrillar \u03b2-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 32:18227\u201318233. https:\/\/doi.org\/10.1523\/JNEUROSCI.3266-12.2012","journal-title":"J Neurosci"},{"key":"5079_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/S00259-008-1039-Z","volume":"36","author":"L Mosconi","year":"2009","unstructured":"Mosconi L, Mistur R, Switalski R et al (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 36:811\u2013822. https:\/\/doi.org\/10.1007\/S00259-008-1039-Z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5079_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1096\/FJ.14-262048\/-\/DC1","volume":"29","author":"D Kapogiannis","year":"2015","unstructured":"Kapogiannis D, Boxer A, Schwartz JB et al (2015) Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer\u2019s disease. FASEB J 29:589\u2013596. https:\/\/doi.org\/10.1096\/FJ.14-262048\/-\/DC1","journal-title":"FASEB J"},{"key":"5079_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3389\/FPHAR.2021.667874\/BIBTEX","volume":"12","author":"Q Chen","year":"2021","unstructured":"Chen Q, Cao T, Li NN et al (2021) Repurposing of anti-diabetic agents as a new opportunity to alleviate cognitive impairment in neurodegenerative and neuropsychiatric disorders. Front Pharmacol 12:1257. https:\/\/doi.org\/10.3389\/FPHAR.2021.667874\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"5079_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/J.CMET.2016.05.011","volume":"23","author":"N Barzilai","year":"2016","unstructured":"Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA (2016) Metformin as a tool to target aging. Cell Metab 23:1060\u20131065. https:\/\/doi.org\/10.1016\/J.CMET.2016.05.011","journal-title":"Cell Metab"},{"key":"5079_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-nutr-071812-161148","volume":"34","author":"DG Hardie","year":"2014","unstructured":"Hardie DG (2014) AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels. Annu Rev Nutr 34:31\u201355. https:\/\/doi.org\/10.1146\/annurev-nutr-071812-161148","journal-title":"Annu Rev Nutr"},{"key":"5079_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2021.09.006","volume":"176","author":"E Barone","year":"2021","unstructured":"Barone E, Di Domenico F, Perluigi M, Butterfield DA (2021) The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radic Biol Med 176:16\u201333. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.09.006","journal-title":"Free Radic Biol Med"},{"key":"5079_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.gendis.2015.12.002","volume":"3","author":"B Zhao","year":"2016","unstructured":"Zhao B, Qiang L, Joseph J et al (2016) Mitochondrial dysfunction activates the AMPK signaling and autophagy to promote cell survival. Genes Dis 3:82\u201387. https:\/\/doi.org\/10.1016\/j.gendis.2015.12.002","journal-title":"Genes Dis"},{"key":"5079_CR24","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1038\/s41467-022-32130-5","volume":"13","author":"A Lee","year":"2022","unstructured":"Lee A, Kondapalli C, Virga DM et al (2022) A\u03b242 oligomers trigger synaptic loss through CAMKK2-AMPK-dependent effectors coordinating mitochondrial fission and mitophagy. Nat Commun 13:4444. https:\/\/doi.org\/10.1038\/s41467-022-32130-5","journal-title":"Nat Commun"},{"key":"5079_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","volume":"69","author":"Z Ou","year":"2018","unstructured":"Ou Z, Kong X, Sun X et al (2018) Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice. Brain Behav Immun 69:351\u2013363. https:\/\/doi.org\/10.1016\/j.bbi.2017.12.009","journal-title":"Brain Behav Immun"},{"key":"5079_CR26","doi-asserted-by":"publisher","unstructured":"Pilipenko V, Narbute K, Pupure J et al (2020) Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer\u2019s disease. Eur J Pharmacol 881. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173290","DOI":"10.1016\/j.ejphar.2020.173290"},{"key":"5079_CR27","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhao J, Guo F-L et al (2020) Metformin ameliorates synaptic defects in a mouse model of AD by inhibiting Cdk5 activity. Front Cell Neurosci 14. https:\/\/doi.org\/10.3389\/fncel.2020.00170","DOI":"10.3389\/fncel.2020.00170"},{"key":"5079_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13195-020-00761-9\/FIGURES\/7","volume":"13","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhao S, Fan Z et al (2021) Metformin attenuates plaque-associated tau pathology and reduces amyloid-\u03b2 burden in APP\/PS1 mice. Alzheimers Res Ther 13:1\u201313. https:\/\/doi.org\/10.1186\/S13195-020-00761-9\/FIGURES\/7","journal-title":"Alzheimers Res Ther"},{"key":"5079_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/J.PBB.2012.03.002","volume":"101","author":"J Li","year":"2012","unstructured":"Li J, Deng J, Sheng W, Zuo Z (2012) Metformin attenuates Alzheimer\u2019s disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 101:564. https:\/\/doi.org\/10.1016\/J.PBB.2012.03.002","journal-title":"Pharmacol Biochem Behav"},{"key":"5079_CR30","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/S00221-021-06176-8","volume":"239","author":"WH Oliveira","year":"2021","unstructured":"Oliveira WH, Braga CF, L\u00f3s DB et al (2021) Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice. Exp Brain Res 239:2821\u20132839. https:\/\/doi.org\/10.1007\/S00221-021-06176-8","journal-title":"Exp Brain Res"},{"key":"5079_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/NEURORX.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3\u201314. https:\/\/doi.org\/10.1602\/NEURORX.2.1.3","journal-title":"NeuroRx"},{"key":"5079_CR32","doi-asserted-by":"publisher","first-page":"120538","DOI":"10.1016\/j.lfs.2022.120538","volume":"299","author":"I Kazkayasi","year":"2022","unstructured":"Kazkayasi I, Telli G, Nemutlu E, Uma S (2022) Intranasal metformin treatment ameliorates cognitive functions via insulin signaling pathway in ICV-STZ-induced mice model of Alzheimer\u2019s disease. Life Sci 299:120538. https:\/\/doi.org\/10.1016\/j.lfs.2022.120538","journal-title":"Life Sci"},{"key":"5079_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/J.TAAP.2009.11.026","volume":"243","author":"MP Quaile","year":"2010","unstructured":"Quaile MP, Melich DH, Jordan HL et al (2010) Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol 243:340\u2013347. https:\/\/doi.org\/10.1016\/J.TAAP.2009.11.026","journal-title":"Toxicol Appl Pharmacol"},{"key":"5079_CR34","doi-asserted-by":"publisher","unstructured":"Iwasaki S, Yamamoto S, Sano N et al (2019) Direct drug delivery of low-permeable compounds to the central nervous system via intranasal administration in rats and monkeys. Pharm Res 36. https:\/\/doi.org\/10.1007\/s11095-019-2613-8","DOI":"10.1007\/s11095-019-2613-8"},{"key":"5079_CR35","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/S12035-015-9132-3","volume":"53","author":"P Grieb","year":"2016","unstructured":"Grieb P (2016) Intracerebroventricular streptozotocin injections as a model of Alzheimer\u2019s disease: in search of a relevant mechanism. Mol Neurobiol 53:1741\u20131752. https:\/\/doi.org\/10.1007\/S12035-015-9132-3","journal-title":"Mol Neurobiol"},{"key":"5079_CR36","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"2007","unstructured":"Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Academic Press, San Diego","edition":"6"},{"key":"5079_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","volume":"31","author":"AM Koenig","year":"2017","unstructured":"Koenig AM, Mechanic-Hamilton D, Xie SX et al (2017) Effects of the insulin sensitizer metformin in Alzheimer\u2019s disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disord 31:107. https:\/\/doi.org\/10.1097\/WAD.0000000000000202","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"5079_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/S10787-022-00980-6","volume":"30","author":"A Hasanvand","year":"2022","unstructured":"Hasanvand A (2022) The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases. Inflammopharmacology 30(3):775\u2013788. https:\/\/doi.org\/10.1007\/S10787-022-00980-6","journal-title":"Inflammopharmacology"},{"key":"5079_CR39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","volume":"62","author":"K \u0141abuzek","year":"2010","unstructured":"\u0141abuzek K, Suchy D, Gabryel B et al (2010) Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 62:956\u2013965. https:\/\/doi.org\/10.1016\/S1734-1140(10)70357-1","journal-title":"Pharmacol Rep"},{"key":"5079_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG, Punt J, Arora M et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81\u201398. https:\/\/doi.org\/10.2165\/11534750-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"5079_CR41","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/S00125-017-4342-Z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60:1577. https:\/\/doi.org\/10.1007\/S00125-017-4342-Z","journal-title":"Diabetologia"},{"key":"5079_CR42","doi-asserted-by":"publisher","unstructured":"Poudel P, Park S (2022) Recent advances in the treatment of Alzheimer\u2019s disease using nanoparticle-based drug delivery systems. Pharmaceutics 14. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14040835","DOI":"10.3390\/PHARMACEUTICS14040835"},{"key":"5079_CR43","doi-asserted-by":"publisher","unstructured":"Fan M, Liu S, Sun HM et al (2022) Bilateral intracerebroventricular injection of streptozotocin induces AD-like behavioral impairments and neuropathological features in mice: involved with the fundamental role of neuroinflammation. Biomed Pharmacother 153. https:\/\/doi.org\/10.1016\/J.BIOPHA.2022.113375","DOI":"10.1016\/J.BIOPHA.2022.113375"},{"key":"5079_CR44","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.3892\/ETM.2018.6487","volume":"16","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Ding R, Wang S et al (2018) Effect of intraperitoneal or intracerebroventricular injection of streptozotocin on learning and memory in mice. Exp Ther Med 16:2375\u20132380. https:\/\/doi.org\/10.3892\/ETM.2018.6487","journal-title":"Exp Ther Med"},{"key":"5079_CR45","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/pharmaceutics14040835","volume":"14","author":"P Poudel","year":"2022","unstructured":"Poudel P, Park S (2022) Recent advances in the treatment of Alzheimer\u2019s disease using nanoparticle-based drug delivery systems. Pharmaceutics 14:835. https:\/\/doi.org\/10.3390\/pharmaceutics14040835","journal-title":"Pharmaceutics"},{"key":"5079_CR46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuint.2017.11.012","volume":"113","author":"SK Mishra","year":"2018","unstructured":"Mishra SK, Singh S, Shukla S, Shukla R (2018) Intracerebroventricular streptozotocin impairs adult neurogenesis and cognitive functions via regulating neuroinflammation and insulin signaling in adult rats. Neurochem Int 113:56\u201368. https:\/\/doi.org\/10.1016\/j.neuint.2017.11.012","journal-title":"Neurochem Int"},{"key":"5079_CR47","doi-asserted-by":"publisher","first-page":"2315106","DOI":"10.1155\/2020\/2315106","volume":"2020","author":"XY Lu","year":"2020","unstructured":"Lu XY, Huang S, Chen QB et al (2020) Metformin ameliorates A\u03b2 pathology by insulin-degrading enzyme in a transgenic mouse model of Alzheimer\u2019s disease. Oxid Med Cell Longev 2020:2315106. https:\/\/doi.org\/10.1155\/2020\/2315106","journal-title":"Oxid Med Cell Longev"},{"key":"5079_CR48","doi-asserted-by":"publisher","first-page":"117861","DOI":"10.1016\/J.LFS.2020.117861","volume":"255","author":"PM Saffari","year":"2020","unstructured":"Saffari PM, Alijanpour S, Takzaree N et al (2020) Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer\u2019s disease model. Life Sci 255:117861. https:\/\/doi.org\/10.1016\/J.LFS.2020.117861","journal-title":"Life Sci"},{"key":"5079_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/JNR.24578","volume":"99","author":"F Kosel","year":"2021","unstructured":"Kosel F, Hamilton JS, Harrison SL et al (2021) Reduced social investigation and increased injurious behavior in transgenic 5xFAD mice. J Neurosci Res 99:209\u2013222. https:\/\/doi.org\/10.1002\/JNR.24578","journal-title":"J Neurosci Res"},{"key":"5079_CR50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/BRB3.41","volume":"2","author":"M Faizi","year":"2012","unstructured":"Faizi M, Bader PL, Saw N et al (2012) Thy1-hAPPLond\/Swe+ mouse model of Alzheimer\u2019s disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav 2:142. https:\/\/doi.org\/10.1002\/BRB3.41","journal-title":"Brain Behav"},{"key":"5079_CR51","doi-asserted-by":"publisher","unstructured":"Deng W, Ke H, Wang S et al (2022) Metformin alleviates autistic-like behaviors elicited by high-fat diet consumption and modulates the crosstalk between serotonin and gut microbiota in mice. Behav Neurol 2022. https:\/\/doi.org\/10.1155\/2022\/6711160","DOI":"10.1155\/2022\/6711160"},{"key":"5079_CR52","doi-asserted-by":"publisher","unstructured":"Wang L, Cai Y, Fan X (2018) Metformin administration during early postnatal life rescues autistic-like behaviors in the BTBR T+ Itpr3tf\/J mouse model of autism. Front Behav Neurosci 12. https:\/\/doi.org\/10.3389\/FNBEH.2018.00290","DOI":"10.3389\/FNBEH.2018.00290"},{"key":"5079_CR53","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903DS1","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang H, Kazi H et al (2012) Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients. J Clin Investig 122:1316\u20131338. https:\/\/doi.org\/10.1172\/JCI59903DS1","journal-title":"J Clin Investig"},{"key":"5079_CR54","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2353\/AJPATH.2009.090157","volume":"175","author":"Y Deng","year":"2009","unstructured":"Deng Y, Li B, Liu Y et al (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain\u202f: implication for Alzheimer\u2019s disease. Am J Pathol 175:2089. https:\/\/doi.org\/10.2353\/AJPATH.2009.090157","journal-title":"Am J Pathol"},{"key":"5079_CR55","doi-asserted-by":"publisher","first-page":"118664","DOI":"10.1016\/J.BBAMCR.2020.118664","volume":"1867","author":"E Lauretti","year":"2020","unstructured":"Lauretti E, Dincer O, Pratic\u00f2 D (2020) Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease. Biochim Biophys Acta (BBA) - Mol Cell Res 1867:118664. https:\/\/doi.org\/10.1016\/J.BBAMCR.2020.118664","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"issue":"7","key":"5079_CR56","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1038\/emm.2016.81","volume":"48","author":"SM Jeon","year":"2016","unstructured":"Jeon SM (2016) Regulation and function of AMPK in physiology and diseases. Exp Mol Med 48(7):e245\u2013e245. https:\/\/doi.org\/10.1038\/emm.2016.81","journal-title":"Exp Mol Med"},{"key":"5079_CR57","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/2211-5463.12436","volume":"8","author":"D Tanokashira","year":"2018","unstructured":"Tanokashira D, Kurata E, Fukuokaya W et al (2018) Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and memory via phosphorylation of insulin receptor substrate 1. FEBS Open Bio 8:1104\u20131118. https:\/\/doi.org\/10.1002\/2211-5463.12436","journal-title":"FEBS Open Bio"},{"key":"5079_CR58","doi-asserted-by":"publisher","unstructured":"Khamies SM, El-Yamany MF, Ibrahim SM (2024) Canagliflozin mitigated cognitive impairment in streptozotocin-induced sporadic Alzheimer\u2019s disease in mice: role of AMPK\/SIRT-1 signaling pathway in modulating neuroinflammation. J Neuroimmune Pharmacol 19. https:\/\/doi.org\/10.1007\/S11481-024-10140-Y","DOI":"10.1007\/S11481-024-10140-Y"},{"key":"5079_CR59","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/S00213-016-4301-2","volume":"233","author":"DK Mostafa","year":"2016","unstructured":"Mostafa DK, Ismail CA, Ghareeb DA (2016) Differential metformin dose-dependent effects on cognition in rats: role of Akt. Psychopharmacology 233:2513\u20132524. https:\/\/doi.org\/10.1007\/S00213-016-4301-2","journal-title":"Psychopharmacology"},{"key":"5079_CR60","doi-asserted-by":"publisher","first-page":"106348","DOI":"10.1016\/J.EJPS.2022.106348","volume":"181","author":"H Kumar","year":"2023","unstructured":"Kumar H, Chakrabarti A, Sarma P et al (2023) Novel therapeutic mechanism of action of metformin and its nanoformulation in Alzheimer\u2019s disease and role of AKT\/ERK\/GSK pathway. Eur J Pharm Sci 181:106348. https:\/\/doi.org\/10.1016\/J.EJPS.2022.106348","journal-title":"Eur J Pharm Sci"},{"key":"5079_CR61","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.2353\/AJPATH.2008.080434","volume":"173","author":"N Louneva","year":"2008","unstructured":"Louneva N, Cohen JW, Han LY et al (2008) Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer\u2019s disease. Am J Pathol 173:1488. https:\/\/doi.org\/10.2353\/AJPATH.2008.080434","journal-title":"Am J Pathol"},{"key":"5079_CR62","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1006\/BBRC.1999.0344","volume":"256","author":"S Shimohama","year":"1999","unstructured":"Shimohama S, Tanino H, Fujimoto S (1999) Changes in caspase expression in Alzheimer\u2019s disease: comparison with development and aging. Biochem Biophys Res Commun 256:381\u2013384. https:\/\/doi.org\/10.1006\/BBRC.1999.0344","journal-title":"Biochem Biophys Res Commun"},{"key":"5079_CR63","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/MP.2016.214","volume":"22","author":"J Chu","year":"2017","unstructured":"Chu J, Lauretti E, Pratic\u00f2 D (2017) Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3\u03b2 kinase: implications for Alzheimer\u2019s disease. Mol Psychiatry 22:1002\u20131008. https:\/\/doi.org\/10.1038\/MP.2016.214","journal-title":"Mol Psychiatry"},{"key":"5079_CR64","doi-asserted-by":"publisher","first-page":"107839","DOI":"10.1016\/J.CELREP.2020.107839","volume":"31","author":"G Park","year":"2020","unstructured":"Park G, Nhan HS, Tyan SH et al (2020) Caspase activation and caspase-mediated cleavage of APP is associated with amyloid \u03b2-protein-induced synapse loss in Alzheimer\u2019s disease. Cell Rep 31:107839. https:\/\/doi.org\/10.1016\/J.CELREP.2020.107839","journal-title":"Cell Rep"},{"key":"5079_CR65","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JAD-140564","volume":"43","author":"LL Du","year":"2015","unstructured":"Du LL, Chai DM, Zhao LN et al (2015) AMPK activation ameliorates Alzheimer\u2019s disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer\u2019s disease model in rats. J Alzheimers Dis 43:775\u2013784. https:\/\/doi.org\/10.3233\/JAD-140564","journal-title":"J Alzheimers Dis"},{"key":"5079_CR66","doi-asserted-by":"publisher","first-page":"6507","DOI":"10.1007\/S12035-016-0169-8","volume":"54","author":"N Rajasekar","year":"2017","unstructured":"Rajasekar N, Nath C, Hanif K, Shukla R (2017) Intranasal insulin administration ameliorates streptozotocin (ICV)-induced insulin receptor dysfunction, neuroinflammation, amyloidogenesis, and memory impairment in rats. Mol Neurobiol 54:6507\u20136522. https:\/\/doi.org\/10.1007\/S12035-016-0169-8","journal-title":"Mol Neurobiol"},{"key":"5079_CR67","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/J.YEXCR.2016.08.013","volume":"347","author":"MC Chiang","year":"2016","unstructured":"Chiang MC, Cheng YC, Chen SJ et al (2016) Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction. Exp Cell Res 347:322\u2013331. https:\/\/doi.org\/10.1016\/J.YEXCR.2016.08.013","journal-title":"Exp Cell Res"},{"key":"5079_CR68","doi-asserted-by":"publisher","unstructured":"Ameen O, Samaka RM, Abo-Elsoud RAA (2022) Metformin alleviates neurocognitive impairment in aging via activation of AMPK\/BDNF\/PI3K pathway. Sci Rep 12. https:\/\/doi.org\/10.1038\/S41598-022-20945-7","DOI":"10.1038\/S41598-022-20945-7"},{"key":"5079_CR69","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/S11011-023-01170-1","volume":"38","author":"M Khaleghi-Mehr","year":"2023","unstructured":"Khaleghi-Mehr M, Delshad AA, Shafie-Damavandi S, Roghani M (2023) Metformin mitigates amyloid \u03b21-40-induced cognitive decline via attenuation of oxidative\/nitrosative stress and neuroinflammation. Metab Brain Dis 38:1127\u20131142. https:\/\/doi.org\/10.1007\/S11011-023-01170-1","journal-title":"Metab Brain Dis"},{"key":"5079_CR70","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s13205-020-02354-7","volume":"10","author":"W Xuan","year":"2020","unstructured":"Xuan W, Wang H, Zhou P et al (2020) Berberine ameliorates rats model of combined Alzheimer\u2019s disease and type 2 diabetes mellitus via the suppression of endoplasmic reticulum stress. 3 Biotech 10:359. https:\/\/doi.org\/10.1007\/s13205-020-02354-7","journal-title":"3 Biotech"},{"key":"5079_CR71","doi-asserted-by":"publisher","first-page":"e17873","DOI":"10.1016\/j.heliyon.2023.e17873","volume":"9","author":"S Rabieipoor","year":"2023","unstructured":"Rabieipoor S, Zare M, Ettcheto M et al (2023) Metformin restores cognitive dysfunction and histopathological deficits in an animal model of sporadic Alzheimer\u2019s disease. Heliyon 9:e17873. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17873","journal-title":"Heliyon"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05079-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:02:15Z","timestamp":1757790135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5079"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05079-x","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}